Company intelligence / Profile preview

Oculinum

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Oculinum was the company responsible for the clinical development and initial FDA approval of Botulinum Toxin Type A for the treatment of strabismus and blepharospasm. The company's lead product, Oculinum, was later rebranded as Botox after acquisition.

Therapeutic areas: NeurologyOphthalmology
Modalities: ProteinBiologic
Industry: Biotech

Partnerships

Smith-Kettlewell Eye Research Institute

Beyond the preview

Go deeper on Oculinum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oculinum.

Explore the full profile